Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 13

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 13
---
 resolution and shorter hospitalization, 
 with no evidence of relapse four weeks post-therapy.                                                                                     |

| · | We previously demonstrated the persistence of AP-SA02 in the IV space on multiple days one hour post IV push. These trial results      
 support AP-SA02 homing to different sites of infection, presumably penetrating biofilms, and infecting and lysing the target S. aureus 
 bacteria, independent of both antibiotic resistance patterns and site of infection.                                                    |

| · | Defined phage variants in AP-SA02 drug product ensure an intrinsic adaptive mechanism — a flexibility that may be key to achieving 
 effective phage therapy from patient to patient.                                                                                   |

| · | We believe that these results strongly support advancement into a pivotal Phase 3 trial that Armata plans to initiate in 2026, subject 
 to review and feedback from the FDA. We are engaged with the FDA regarding a potential superiority trial design.                       |

On October 22, 2025, we highlighted the positive results from our Phase 2a diSArm clinical study of AP-SA02 in an oral presentation at IDWeek 2025 TM. The abstract, titled, “A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia,” was accepted as a late-breaking abstract for oral presentation, and was presented by Dr. Loren G. Miller, M.D., M.P.H., Professor of Medicine, David Geffen School of Medicine at UCLA, Chief, Division of Infectious Diseases at Harbor-UCLA Medical Center and the Lundquist Institute.

<div align='center'>S-8</div>

The results from our
Phase 1b/2a diSArm study are an important step forward in our effort to confirm the potent antimicrobial activity of phage therapy and
the completion of the study represents a significant milestone in the development of AP-SA02, moving us one step closer to introducing
an effective new treatment option to patients suffering from complicated SAB. This is the first clear evidence in a randomized controlled
trial of the efficacy of phage against a serious systemic pathogen that is responsible for significant morbidity and mortality in the
United States.

Findings from the Phase
1b/2a study, including the favorable safety and toler